Congrats Patricia and team!

Congrats Leire! 🎊

Congrats Mara and team!

Enhorabuena!!!

Hi! Can I be added please? 😃

Thanks Raquel!

It's true that the #TIGIT space has seen ups and downs in the last few years. Curious to see clinical trials implementing better patient stratification strategies based on epithelial/mesenchymal markers to improve responses to #immunotherapy!

Hi Jon! I'd love to join as well!!

5️⃣ Many more insights in the main article and supplementary material, so have a closer look to all our findings! Hope you enjoy the reading, it’s been a long and challenging ride but we are one step closer to defeat #cancer! 👩🏻‍🔬

4️⃣ Finally, the enrichment of mesenchymal cancer cells and the change in the IC ligand repertoire towards CD80/CD155 predicts response to anti-PD-1/PD-L1 in cSCC, HNSCC & melanoma patient samples, revealing the importance of cancer cell heterogeneity as indicative of responsiveness

3️⃣ Epithelial cSCCs respond to anti-PD-1/L1 therapies, whereas mesenchymal cSCCs respond to anti-CTLA-4 and anti-TIGIT therapies. The anti-PD-L1/TIGIT combination is the most effective strategy for blocking the growth of cSCCs containing both epithelial and mesenchymal cancer cells

2️⃣ Using a cSCC model, we reveal that cancer cells change their IC ligand profile according to their epithelial/mesenchymal features, dictating the IC pathways involved in immune evasion: epithelial cancer cells via PD-1/L1 and mesenchymal cancer cells via CTLA-4/CD80 & TIGIT/CD155

1️⃣ Immune checkpoint inhibitors have changed the therapeutic landscape for many tumors. However, many patients don't respond/develop resistance. This motivated us to unravel why this occurs and whether we could enhance antitumor responses in cutaneous squamous cell carcinoma (cSCC)